Merck's Acquisition of EyeBio Finalized
Merck's Acquisition of EyeBio Finalized
Merck (NYSE:MRK) is trending on Friday. The company announced the acquisition of EyeBio, introducing a novel candidate to Merk's pipeline, Restoret.
默沙東（紐交所：MRK）正在本週五受關注。該公司宣佈收購眼科公司EyeBio，引入了一個新的候選藥物Restoret到默沙東的管線中。
What To Know: Restoret has shown promising results in a Phase 1b/2a AMARONE study in participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).
了解一下：Restoret在1b/2a AMARONE研究中向參與人員展示了有希望的結果，適用於糖尿病性黃斑水腫（DME）和新生老年性黃斑變性（NVAMD）
The treatment is anticipated to advance to a Phase 2b/3 trial to further assess its potential as a treatment for DME later this year.
該治療預計將在今年晚些時候進入2b/3期試驗，以進一步評估其作爲DME治療方法的潛力。
"The EyeBio acquisition further diversifies our late-stage pipeline with the addition of a promising candidate based on novel biology and genetics for the treatment of certain retinal diseases," said Dean Y. Li, president, Merck Research Laboratories. "We are excited to welcome the EyeBio team and look forward to working together to advance Restoret for the patients that need it."
"通過基於新的生物學和遺傳學的有前途的候選藥物，收購EyeBio進一步使我們的後期階段管線多樣化，用於治療某些視網膜疾病。"默沙東研究實驗室的總裁Dean Y. Li說:"我們很興奮能夠歡迎EyeBio團隊，並期待着與他們合作，推進Restoret爲需要它的患者服務。"
Other potential pipeline candidates consist of clinical and preclinical assets being developed to prevent and treat vision loss linked to retinal vascular leakage, which is a recognized risk factor for retinal diseases.
其他可能的管線候選藥物包括正在開發用於預防和治療與視網膜血管滲漏相關的視力損失的臨床和臨床前資產。這是許多視網膜疾病的公認風險因素。
MRK Price Action: At the time of writing, Merck stock is trading 0.57% lower at $128.22, according to data from Benzinga Pro.
MRK股價變動：根據Benzinga Pro的數據，撰寫本文時，默克股票交易價格爲128.22美元，較低0.57%。
Image: Photo via Company
圖片：通過公司提供的照片
譯文內容由第三人軟體翻譯。